Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Question

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jan 31, 2024 6:29pm

166 Views

Post# 35855988

RE:RE:Question

Thanks Enrique. If you subtract that 8 from the 14 NR at every evaluation it looks like only 6 patients had no response at any time.

enriquesuave wrote: Maximum 19 of these 27 patients got a 2nd treatment as 8 undertreated patients were dropped from trial early on before 2nd treatment. The rest of the 19?

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023